NCT02888379View on ClinicalTrials.gov

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions

Ulcerative Colitis

Interventions

DRUG

TOP1288

DRUG

Placebo (for TOP1288)

Trial Locations (28)

Unknown

Plovdiv

Sofia

Brno

Litoměřice

Olomouc

Prague

Budapest

Gyöngyös

Győr

Gyula

Szeged

Székesfehérvár

Vác

Daugavpils

Riga

Kaunas

Bydgoszcz

Knurów

Skierniewice

Sopot

Warsaw

Wroclaw

Kherson

Kyiv

Odesa

Temopil

Zaporizhzhia

London

All Listed Sponsors

lead

Topivert Pharma Ltd

INDUSTRY

NCT02888379 - Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis | Biotech Hunter | Biotech Hunter